TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24216139

Group type: EXPERIMENTAL
Intervention: ColoDATES Web (interactive decision aid)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Non-interactive website (control)
Number of subjects: 600
Study: 21364895

Group type: EXPERIMENTAL
Intervention: Chord progressions with varying conditional probabilities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Musical training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral measures in non-musicians
Number of subjects: 0
Study: 18272934

Group type: EXPERIMENTAL
Intervention: Ex+D (cycling exercise at 65% of oxygen consumption reserve, 200 kcal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Protein meal (43% protein, 30% carbohydrate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prior exercise (Ex+D)
Number of subjects: 20
Study: 16817279

Group type: EXPERIMENTAL
Intervention: Modified Pinellia Decoction for Draining the Heart
Number of subjects: 78

Group type: COMPARATOR
Intervention: Jinsang Liyan Wan (Pills for a Good Voice by Relieving Sore‐Throat)
Number of subjects: 78
Study: 14510744

Group type: EXPERIMENTAL
Intervention: Oral esomeprazole (40 mg o.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous pantoprazole (40 mg o.d.)
Number of subjects: 30
Study: 10981843

Group type: EXPERIMENTAL
Intervention: Expressive suppression during film viewing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expressive suppression during slide viewing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typical expressive suppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 0
Study: 9213835

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 30
Study: 1316307

Group type: EXPERIMENTAL
Intervention: Cryotherapy plus subcutaneous interferon (IFN) alpha 2a
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 30
Study: 3927805

Group type: EXPERIMENTAL
Intervention: 10 mg of diazepam orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31357949

Group type: EXPERIMENTAL
Intervention: Interdisciplinary Home‐bAsed Reablement Program (I‐HARP)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: I‐HARP
Number of subjects: 176
Study: 29316236

Group type: EXPERIMENTAL
Intervention: Tofogliflozin (tofo-tofo group)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo followed by Tofogliflozin (pla-tofo group)
Number of subjects: 210
Study: 26707354

Group type: EXPERIMENTAL
Intervention: Propranolol (1 mg/kg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 24460905

Group type: EXPERIMENTAL
Intervention: Support group intervention for children in troubled families
Number of subjects: 116

Group type: COMPARATOR
Intervention: Waiting list control group (care as usual)
Number of subjects: 116
Study: 22488557

Group type: EXPERIMENTAL
Intervention: Glucagon (0.5 mg) administered intravenously during endoscopy (GL group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Scopolamine butylbromide (10 mg) administered intravenously during endoscopy (SC group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No medications used prior to PET (NO group)
Number of subjects: 30
Study: 19757017

Group type: EXPERIMENTAL
Intervention: 0.1% UC781 gel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.25% UC781 gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 36
Study: 17391324

Group type: EXPERIMENTAL
Intervention: CYP3A5*1/*1 or *1/*3 genotype
Number of subjects: 29

Group type: COMPARATOR
Intervention: CYP3A5*3/*3 genotype
Number of subjects: 29

Group type: COMPARATOR
Intervention: MDR1 diplotypes (CGC‐CGC, CGC‐TTT, CGC‐TGC, TTT‐TGC, TTT‐TTT)
Number of subjects: 29
Study: 14966345

Group type: EXPERIMENTAL
Intervention: IVCA-cryo
Number of subjects: 50

Group type: COMPARATOR
Intervention: IVCA
Number of subjects: 50
Study: 11602495

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 4453

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4453
Study: 9639377

Group type: EXPERIMENTAL
Intervention: Rapid atrial pacing (10 minutes)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Verapamil infusion
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Other antiarrhythmic drugs (procainamide, propafenone, propranolol, dl-sotalol, amiodarone)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pacing-induced AF
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All antiarrhythmic drugs
Number of subjects: 70
Study: 7990854

Group type: EXPERIMENTAL
Intervention: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) at a mean dose of 37 +/- 10 mg intramuscularly
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) co-administered with a mildly dyskinetic dose of levodopa infused intravenously
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) at low doses (2.5 and 5 mg)
Number of subjects: 9
Study: 2732639

Group type: EXPERIMENTAL
Intervention: Phototherapy with lactose formula
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Phototherapy with non-lactose formula
Number of subjects: 25
Study: 31958428

Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 8838

Group type: EXPERIMENTAL
Intervention: Adherent to bisphosphonate therapy
Number of subjects: 8838

Group type: EXPERIMENTAL
Intervention: Concomitant users of vitamin D and calcium and a bisphosphonate
Number of subjects: 8838

Group type: EXPERIMENTAL
Intervention: More than 1 fracture on different dates during the study period
Number of subjects: 8838

Group type: EXPERIMENTAL
Intervention: Underwent DXA testing prior to bisphosphonate prescription and incident fracture
Number of subjects: 8838
Study: 29555258

Group type: EXPERIMENTAL
Intervention: mXELIRI with or without bevacizumab
Number of subjects: 650

Group type: COMPARATOR
Intervention: FOLFIRI with or without bevacizumab
Number of subjects: 650
Study: 28778994

Group type: EXPERIMENTAL
Intervention: Novel prehabilitation protocol (10-day bundle of interventions: physiotherapy, nutritional supplementation, cognitive training)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 62
Study: 26632301

Group type: EXPERIMENTAL
Intervention: Experimental group received a video demonstration and participated in a discussion and analysis of the control group's videotaped performance.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received a video demonstration of the exercise.
Number of subjects: 60
Study: 24283172

Group type: EXPERIMENTAL
Intervention: Estradiol hemihydrate 2 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: No menopausal therapy (Control)
Number of subjects: 52
Study: 20864469

Group type: EXPERIMENTAL
Intervention: Continuous wave signal at 385.25 MHz
Number of subjects: 120

Group type: COMPARATOR
Intervention: 16 Hz pulsing signal
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 120
Study: 18462083

Group type: EXPERIMENTAL
Intervention: Discrete genotypic susceptibility score (dGSS)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Continuous genotypic susceptibility score (cGSS)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Genotypic susceptibility scores (GSS)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Protease mutations at codons 24 and 90
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Mutations at codon 82
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: NNRTI-associated mutations (K103N)
Number of subjects: 234
Study: 16574815

Group type: EXPERIMENTAL
Intervention: Cognitive bibliotherapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Individual cognitive psychotherapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cognitive bibliotherapy and Individual cognitive psychotherapy
Number of subjects: 23
Study: 12814333

Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg/day
Number of subjects: 1079

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1079
Study: 15877555

Group type: EXPERIMENTAL
Intervention: Nonpharmacological intervention (5 consecutive days and nights of efforts to decrease daytime in-bed time, 30 minutes or more of daily sunlight exposure, increased physical activity, structured bedtime routine, and efforts to decrease nighttime noise and light)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Nonpharmacological intervention
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 118
Study: 10328256

Group type: EXPERIMENTAL
Intervention: Vigabatrin (50 to 60 mg/kg per day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Carbamazepine (15 to 20 mg/kg per day)
Number of subjects: 70
Study: 8960948

Group type: EXPERIMENTAL
Intervention: Arbutamine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Arbutamine and Exercise
Number of subjects: 45
Study: 2022014

Group type: EXPERIMENTAL
Intervention: Aspirin 324 mg daily
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 6807469

Group type: EXPERIMENTAL
Intervention: Combined alpha-blockade and beta-blockade with labetalol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Beta-blockade with propranolol
Number of subjects: 12
Study: 28689679

Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 110
Study: 25496464

Group type: EXPERIMENTAL
Intervention: Tofacitinib 1 mg BID
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Tofacitinib 3 mg BID
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg BID
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 25234524

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bur removal (traditional technique)
Number of subjects: 100
Study: 22549298

Group type: EXPERIMENTAL
Intervention: Empathy training modules (three 60-minute sessions)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard post-graduate medical education
Number of subjects: 99
Study: 19631946

Group type: EXPERIMENTAL
Intervention: Losartan-based regimens
Number of subjects: 9193
Study: 17322494

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 60 microg/kg daily
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) (15, 30 microg/kg daily)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 406
Study: 15460882

Group type: EXPERIMENTAL
Intervention: Experimental tracking optical coherence tomography (OCT) system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite OCT images averaged over multiple scans and visits
Number of subjects: 0
Study: 11245709

Group type: EXPERIMENTAL
Intervention: Baclofen (20 mg three times daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9716583

Group type: EXPERIMENTAL
Intervention: G‐CSF (5 microgram/kg/d) subcutaneously
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 198
Study: 8037160

Group type: EXPERIMENTAL
Intervention: Sensitive thromboplastin (ISI, 1.3)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard thromboplastin (ISI, 1.9)
Number of subjects: 84
Study: 3230200

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 30482460

Group type: EXPERIMENTAL
Intervention: Tai Chi (TCh)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Postural Control (CP) exercises
Number of subjects: 125
Study: 29283609

Group type: EXPERIMENTAL
Intervention: Helping for Health Inventory‐Couples Version (HHI‐C)
Number of subjects: 268
Study: 26503137

Group type: EXPERIMENTAL
Intervention: Oral liquid nutrition supplement (ONS) intervention
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Snack intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: ONS intervention
Number of subjects: 154
Study: 23351730

Group type: EXPERIMENTAL
Intervention: Long leg cast immobilization until postoperative week 5, followed by a 0° locking brace until week 12.
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0° locking brace until postoperative week 12 without cast immobilization.
Number of subjects: 44
Study: 21249386

Group type: EXPERIMENTAL
Intervention: Prolonged strenuous exercise (60 min at 75% effort)
Number of subjects: 10
Study: 19917874

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Combination therapy (Hydrochlorothiazide and Atenolol)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Hydrochlorothiazide strategy
Number of subjects: 395

Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 395

Group type: COMPARATOR
Intervention: Uric acid
Number of subjects: 395
Study: 17416123

Group type: EXPERIMENTAL
Intervention: Anterior glide mobilization
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Posterior glide mobilization
Number of subjects: 20
Study: 15815207

Group type: EXPERIMENTAL
Intervention: Employment status (full-time and part-time)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Quality of life (Inflammatory Bowel Disease Questionnaire, Short Form-36)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Factors associated with unemployment
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Factors associated with receiving disability compensation
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Employment status of unemployed patients
Number of subjects: 225
Study: 12039398

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy, 40-60 sessions of oxygen breathing at 2.5-bar increased pressure in a hyperbaric chamber
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy
Number of subjects: 38
Study: 10607254

Group type: EXPERIMENTAL
Intervention: High-dose, short-duration interferon-alpha2b (10 million units for 14 weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard interferon regimen (3 MU three times weekly for 6 months)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High-dose, short-duration interferon-alpha2b
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard interferon regimen
Number of subjects: 58
Study: 8607618

Group type: COMPARATOR
Intervention: CAF + TAM therapy (Arm A)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: CAF + MPA therapy (Arm B)
Number of subjects: 114
Study: 2182234

Group type: EXPERIMENTAL
Intervention: Intravenous anistreplase (APSAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracoronary streptokinase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study: 6933004

Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: No BCG immunotherapy
Number of subjects: 24
Study: 30545701

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0μg·kg‐1 i.v.)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Labetalol (0.3 mg·kg‐1 i.v.)
Number of subjects: 160
Study: 28964366

Group type: EXPERIMENTAL
Intervention: 500mL of a functional beverage enriched with 200mL of grape pomace (GP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 500mL of a control beverage without grape pomace (GP)
Number of subjects: 12
Study: 25682576

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (15 or 20 mg twice a day)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 23832291

Group type: EXPERIMENTAL
Intervention: Phonophoresis (PH)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Short-wave diathermy (SWD)
Number of subjects: 101
Study: 21791454

Group type: EXPERIMENTAL
Intervention: hylan G-F 20 (Synvisc)
Number of subjects: 151

Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 151
Study: 19351941

Group type: EXPERIMENTAL
Intervention: Usual care plus aerobic exercise training (36 supervised sessions followed by home-based training)
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Usual care plus aerobic exercise training
Number of subjects: 2331

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 2331
Study: 16776357

Group type: EXPERIMENTAL
Intervention: X STOP IPD device
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 75
Study: 15005950

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet and lifestyle advice
Number of subjects: 0
Study: 11706929

Group type: EXPERIMENTAL
Intervention: Computer decision support software
Number of subjects: 447

Group type: COMPARATOR
Intervention: Control (no software)
Number of subjects: 447
Study: 9415336

Group type: EXPERIMENTAL
Intervention: 16 mg ondansetron suppository once a day
Number of subjects: 420

Group type: COMPARATOR
Intervention: 8 mg intravenous ondansetron on day 1 followed by 8 mg tablet twice daily on days 2 and 3 (i.v. + p.o. group)
Number of subjects: 420
Study: 8424510

Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine (20 mL of 1.37% lidocaine plus 1 mL sodium bicarbonate per 10 mL 1.5% lidocaine)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-alkalinized lidocaine (20 mL of 1.37% lidocaine with added 1:200,000 epinephrine)
Number of subjects: 26
Study: 3310622

Group type: EXPERIMENTAL
Intervention: Transscrotal testosterone system
Number of subjects: 3

Group type: COMPARATOR
Intervention: 200 mg of testosterone enanthate
Number of subjects: 3
Study: 29016466

Group type: EXPERIMENTAL
Intervention: Simulation-based teaching method
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 30
Study: 27281019

Group type: EXPERIMENTAL
Intervention: Pegylated interferon‐alfa‐2a (Peg‐IFN‐α) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nucleos(t)ide analog alone or in combination with Peg‐IFN‐α
Number of subjects: 0
Study: 24487733

Group type: EXPERIMENTAL
Intervention: Ringer's Lactate (LR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 40
Study: 22385565

Group type: EXPERIMENTAL
Intervention: Quantum BioEnergetics (QBE) healing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 0
Study: 20604704

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 18781090

Group type: EXPERIMENTAL
Intervention: MRI axial length measurement
Number of subjects: 20

Group type: COMPARATOR
Intervention: A-scan ultrasonography axial length measurement
Number of subjects: 20
Study: 15000216

Group type: EXPERIMENTAL
Intervention: Point-of-care testing of troponin T
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Point-of-care testing of myoglobin
Number of subjects: 741

Group type: COMPARATOR
Intervention: Laboratory-based method for troponin T
Number of subjects: 741
Study: 12224570

Group type: EXPERIMENTAL
Intervention: Chloroquine combined with primaquine (25 mg/kg in 3 doses over 48 hours + 30 mg primaquine daily for 28 days)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo of primaquine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Chloroquine combined with primaquine
Number of subjects: 53
Study: 9833916

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Somatostatin infusion (250 microg/h after a 250‐microg bolus for 5 days)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Somatostatin infusion
Number of subjects: 169
Study: 7855216

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg) administered daily for 8 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2764595

Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study: 154164

Group type: EXPERIMENTAL
Intervention: Ipratropium (Atrovent)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 31087085

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 27862658

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (4g in 5% dextrose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 12
Study: 25841959

Group type: EXPERIMENTAL
Intervention: 4% buffered lidocaine with 1:100,000 epinephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: 4% lidocaine with 1:100,000 epinephrine (nonbuffered)
Number of subjects: 100
Study: 24379592

Group type: EXPERIMENTAL
Intervention: Somatostatin and dexamethasone treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Total parenteral nutrition and nasogastric (NG) tube feeding (Control)
Number of subjects: 70
Study: 21757237

Group type: EXPERIMENTAL
Intervention: Standardized stepwise treatment regimen (SSTR)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 148
Study: 19420283

Group type: EXPERIMENTAL
Intervention: medium‐chain triglycerides/long‐chain triglycerides (soybean oil; MCT/LCT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: olive/soybean oil (oleic)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: long‐chain triglycerides (soybean oil; LCT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: structured lipid
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (MCT/LCT and oleic groups)
Number of subjects: 28
Study: 16883525

Group type: EXPERIMENTAL
Intervention: High calcium group (1000 mg element calcium and 400 units of vitamin D daily for 12 months)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low calcium group (300 mg element calcium and 300 units of vitamin D daily for 12 months)
Number of subjects: 200